Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In patients with post-myocardial infarction ventricular septal defects, temporary left ventricular support using Impella 5.5 can decrease shunting, facilitate peri-infarct tissue remodeling, and allow for assessment of myocardial recovery prior to repair. When there is inadequate cardiac recovery, implantation of a durable left ventricular assist device such as HeartMate 3 at time of repair can be safely performed. A right ventriculotomy provides multiple advantages when performing VSD repair and concomitant HeartMate 3 placement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/aor.14857 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ischemic heart disease.
J Sports Med Phys Fitness
August 2025
Division of University Cardiology and Cardiac Imaging, IRCCS Galeazzi Sant'Ambrogio Hospital, Milan, Italy -
The new section on ischemic heart disease (IHD) among the Italian Sports Cardiology Guidelines (COCIS) provides updated recommendations for the evaluation, management and eligibility of athletes with known or suspected IHD. Emphasizing a risk-stratified approach, the guidelines integrate clinical, functional, and imaging assessments to determine the safety of competitive sports participation. Key updates include considerations for athletes with asymptomatic or subclinical disease.
View Article and Find Full Text PDFMETTL3 Silencing Suppresses Cardiac Fibrosis Post Myocardial Infarction via m6A Modification of SMOC2.
J Cell Mol Med
September 2025
Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Cardiac fibrosis, especially in the infarct border zone, leads to decreased cardiac compliance, impaired systolic and diastolic function, resulting in heart failure. M6A methylation plays a role in fibrosis development. However, its underlying mechanism remains poorly understood.
View Article and Find Full Text PDFUsing modified mRNA for cardiomyocyte proliferation and cardiac genetic disease modelling and treatment.
Biochem Soc Trans
September 2025
Department of Pharmacology, University of Cambridge, Cambridge, CB2 1PD, U.K.
Heart failure (HF) is a leading cause of death worldwide and the associated mortality and socioeconomic burden is predicted to worsen. Current therapies for HF focus on managing the causes and symptoms; however, these current treatment options are unable to reverse heart muscle degeneration, with heart transplantation the only cure. The ability to re-muscularise the heart represents a significant unmet clinical need.
View Article and Find Full Text PDFCardiac Homing Peptide-Functionalized Polymeric Nanoparticles Suppressing SHP1 Alleviate Acute Myocardial Infarction Injury by Promoting Efferocytosis and Inhibiting Inflammation.
Int J Nanomedicine
September 2025
State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Purpose: Acute myocardial infarction (AMI) is a major global health concern worldwide. The upregulation of the CD47 on apoptotic cardiomyocytes acts as a "don't-eat-me" signal, inhibiting the clearance of apoptotic cells by macrophages (a process known as efferocytosis) via the Signal Regulatory Protein α (SIRPα)/ SH2 Domain-Containing Phosphatase 1 (SHP1) axis, leading to secondary inflammatory activation. Additionally, impairment of this process can result in insufficient macrophage polarization towards the reparative M2 phenotype.
View Article and Find Full Text PDF